ArticleAorta (Stamford, Conn.)2026
Early Single-Center Experience with the Ascyrus Medical Dissection Stent in Acute Type A Aortic Dissection Repair.
Article in Aorta (Stamford, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute Type A aortic dissection (ATAAD) is a cardiac surgical emergency associated with high rates of mortality and morbidity. The Ascyrus Medical Dissection Stent (AMDS) is a novel hybrid device that has demonstrated promise in stabilizing the aortic arch, eliminating distal anastomosis new reentry tears and improving malperfusion syndromes. This report examines early outcomes of ATAAD patients treated with the AMDS device compared with a sole hemiarch repair. Methods: This retrospective study included all patients who underwent emergency surgery for computed tomography confirmed ATAAD at our center from January 2024 to November 2025. Iatrogenic, subacute, and chronic dissections were excluded from the study as were patients who received any form of arch surgery. Results: Six patients received the AMDS device and hemiarch, whereas 18 patients received a hemiarch repair only. A 30-day mortality was 16.7 and 22.2% in the AMDS and hemiarch cohorts, respectively ( Conclusion: This study has demonstrated the relative safety of the AMDS device when used as an adjunct to the standard hemiarch repair in the management of ATAAD patients. Long-term outcome data are required to determine the extent of the positive aortic remodeling effect of the AMDS device and its impact on aortic reintervention and survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.